中华诊断学电子杂志
中華診斷學電子雜誌
중화진단학전자잡지
2014年
3期
198-201
,共4页
孔令斌%王茜%王一波%李洪运
孔令斌%王茜%王一波%李洪運
공령빈%왕천%왕일파%리홍운
聚乙烯二醇类%氟尿嘧啶%白蛋白类%微球体%肠肿瘤%小鼠,裸
聚乙烯二醇類%氟尿嘧啶%白蛋白類%微毬體%腸腫瘤%小鼠,裸
취을희이순류%불뇨밀정%백단백류%미구체%장종류%소서,라
Polyethylene glycds%Fluorouracil%Albumins%Microspheres%Intestinal%Mice,nude
目的：探讨聚乙二醇（PEG）修饰的5-氟尿嘧啶磁性白蛋白微球（PEG-5-Fu-MAMS）和5-氟尿嘧啶磁性白蛋白微球（5-Fu-MAMS）对大肠癌组织的被动靶向性。方法20只人大肠癌裸鼠随机数字表法分为 PEG-5-Fu-MAMS 组、5-Fu-MAMS 组，每组10只，分别将2种不同的制剂（按8 mg/kg5-Fu）经尾静脉给药，在磁场下30 min 后，经眼眶采血，处死大鼠，用高效液相色谱法测定肿瘤组织、血清和肾脏组织中5-Fu 的水平。采用 SPSS 13．0软件对资料进行统计分析，两组不同组织中5-Fu 水平以 x ±s 记录，显著性检验采用 t 检验。结果注射 PEG-5-Fu-MAMS 组大肠癌组织中的5-Fu水平为（51．21±2．12）μg/mL，明显高于5-Fu-MAMS 组的（33．07±8．21）μg/mL（t ＝78．69， P＜0．05）；而在注射 PEG-5-Fu-MAMS 组的血清中5-Fu 的水平为（1．69±0．53）μg/mL，则明显低于5-Fu-MAMS 组的（6．78±0．23）μg/mL（t ＝18．76，P＜0．05）；在肾脏中 PEG-5-Fu-MAMS 组药5-Fu 水平为（21．1±2．3）μg/mL，明显低于5-Fu-MAMS 组的（38．2±4．9）μg/mL（t ＝39．23，P ＜0．05）。结论PEG-5-Fu-MAMS 比5-Fu-MAMS 的亲大肠癌作用强，PEG-5-Fu-MAMS 有望成为一种新的靶向治疗大肠癌的药物。
目的：探討聚乙二醇（PEG）脩飾的5-氟尿嘧啶磁性白蛋白微毬（PEG-5-Fu-MAMS）和5-氟尿嘧啶磁性白蛋白微毬（5-Fu-MAMS）對大腸癌組織的被動靶嚮性。方法20隻人大腸癌裸鼠隨機數字錶法分為 PEG-5-Fu-MAMS 組、5-Fu-MAMS 組，每組10隻，分彆將2種不同的製劑（按8 mg/kg5-Fu）經尾靜脈給藥，在磁場下30 min 後，經眼眶採血，處死大鼠，用高效液相色譜法測定腫瘤組織、血清和腎髒組織中5-Fu 的水平。採用 SPSS 13．0軟件對資料進行統計分析，兩組不同組織中5-Fu 水平以 x ±s 記錄，顯著性檢驗採用 t 檢驗。結果註射 PEG-5-Fu-MAMS 組大腸癌組織中的5-Fu水平為（51．21±2．12）μg/mL，明顯高于5-Fu-MAMS 組的（33．07±8．21）μg/mL（t ＝78．69， P＜0．05）；而在註射 PEG-5-Fu-MAMS 組的血清中5-Fu 的水平為（1．69±0．53）μg/mL，則明顯低于5-Fu-MAMS 組的（6．78±0．23）μg/mL（t ＝18．76，P＜0．05）；在腎髒中 PEG-5-Fu-MAMS 組藥5-Fu 水平為（21．1±2．3）μg/mL，明顯低于5-Fu-MAMS 組的（38．2±4．9）μg/mL（t ＝39．23，P ＜0．05）。結論PEG-5-Fu-MAMS 比5-Fu-MAMS 的親大腸癌作用彊，PEG-5-Fu-MAMS 有望成為一種新的靶嚮治療大腸癌的藥物。
목적：탐토취을이순（PEG）수식적5-불뇨밀정자성백단백미구（PEG-5-Fu-MAMS）화5-불뇨밀정자성백단백미구（5-Fu-MAMS）대대장암조직적피동파향성。방법20지인대장암라서수궤수자표법분위 PEG-5-Fu-MAMS 조、5-Fu-MAMS 조，매조10지，분별장2충불동적제제（안8 mg/kg5-Fu）경미정맥급약，재자장하30 min 후，경안광채혈，처사대서，용고효액상색보법측정종류조직、혈청화신장조직중5-Fu 적수평。채용 SPSS 13．0연건대자료진행통계분석，량조불동조직중5-Fu 수평이 x ±s 기록，현저성검험채용 t 검험。결과주사 PEG-5-Fu-MAMS 조대장암조직중적5-Fu수평위（51．21±2．12）μg/mL，명현고우5-Fu-MAMS 조적（33．07±8．21）μg/mL（t ＝78．69， P＜0．05）；이재주사 PEG-5-Fu-MAMS 조적혈청중5-Fu 적수평위（1．69±0．53）μg/mL，칙명현저우5-Fu-MAMS 조적（6．78±0．23）μg/mL（t ＝18．76，P＜0．05）；재신장중 PEG-5-Fu-MAMS 조약5-Fu 수평위（21．1±2．3）μg/mL，명현저우5-Fu-MAMS 조적（38．2±4．9）μg/mL（t ＝39．23，P ＜0．05）。결론PEG-5-Fu-MAMS 비5-Fu-MAMS 적친대장암작용강，PEG-5-Fu-MAMS 유망성위일충신적파향치료대장암적약물。
Objective To explore passive targeting property of Polyethylene glycol (PEG)modification of 5-fluorouracil magnetic albumin microspheres (PEG 5-Fu-MAMS)and 5-fluorouracil magnetic albumin microspheres (Fu-MAMS)for colorectal cancer tissus.Methods Twenty mice were randomly divided into Group 5-Fu-MAMS(n =1 0)and Group PEG-5-Fu-MAMS(n =1 0).They were injected through the vena caudalis at the dose of 8 mg/kg of free drug respectively.After a magnetic field for 30 minutes,the mice were killed,the orbital cavity blood was sampled immediately.The concentrations of 5-fluorouracil in colorectal carcinoma and renal tissue and serum were determined by the high performance liquid chromatography (HPLC).The difference of the level of 5-Fu was compared with t -test.Results The 5-Fu concentration of colorectal carcinoma in PEG-5-Fu-MS (51 .21 ±2.1 2)μg/mL group was significantly higher than that of 5-Fu-MS group[(33.07 ±8.21 )μg/mL,t =78.69,P <0.05].But the 5-Fu concentration of serum in PEG-5-Fu-MAMS [(1 .69 ±0.53)μg/mL]was significantly lower than that of 5-Fu-MAMS group[(6.78 ±0.23)μg/mL,t =1 8.76,P<0.05].The 5-Fu concentration of kidney tissue in PEG-5-Fu-MAMS group (21 .1 ±2.3)μg/mL was significantly lower than that of the 5-Fu-MAMS group [(38.2 ±4.9)μg/mL,t =39.23,P <0.05)].Conclusions The study suggests that the affinity with colorectal cancer of PEG-5-FU-MASA to colorectal cancer is stronger than that of the 5-FU-MAMS .PEG-5-FU-MAMS are expected to become a new targeted therapy of colorectal cancer.
